Company: ZLAB
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001628280-25-018384
Chunk: 42

Company: Zai Lab Ltd
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 42
---
 Chief Legal Officer and Corporate Secretary                                 |
| Josh Smiley        |     | President and Chief Operating Officer                                       |

### EXECUTIVE SUMMARY

### 2024 Business Highlights
2024 marked another year of strong growth and execution for Zai Lab. We delivered on our strategic priorities, achieved robust commercial performance, including 50% year-over-year growth in total revenue driven by strong demand for our products, and continued to advance and expand our pipeline of innovative product candidates. Key highlights include the following:

• Improved Access for Our Commercial Products: We continued to drive revenue growth in 2024 through our focus on improved access for our commercial products, and this growth was primarily driven by VYVGART, ZEJULA, and NUZYRA. VYVGART has steadily increased sales since its strong commercial launch in September 2023 and initial listing in China’s National Reimbursement Drug List (“NRDL”) in January 2024. ZEJULA, which was first added to the NRDL in December 2020, continued to lead PARP inhibitor sales for ovarian cancer in the hospital setting in mainland China. NUZYRA sales have continued to grow, supported by the inclusion in the NRDL of its IV formulation for the treatment of CABP and/or ABSSSI in January 2023 and its oral formulation for these indications in January 2024.

• Launch of Additional Commercial Products: As a result of our strong efforts in 2024, we are excited to have expanded our commercial portfolio from five to eight products with the launch in mainland China of VYVGART Hytrulo, the subcutaneous formulation of efgartigimod, for generalized myasthenia gravis (“gMG”) and chronic inflammatory demyelinating polyneuropathy (“CIDP”), XACDURO for hospital-acquired bacterial pneumonia and ventilator associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex (“ABC”), and AUGTYRO for ROS1+ non-small cell lung cancer. AUGTYRO was included in the NRDL for this indication in January 2025.

• Development of our Pipeline: We have a deep and differentiated pipeline of innovative products across our therapeutic areas of oncology, immunology, neuroscience, and infectious disease, including several in late-stage clinical development. Our product pipeline continues to demonstrate potential best-in-class and/or first-in-class profiles. During 2024, for our global assets, we had promising results from the global Phase I study